Stock Scorecard



Stock Summary for Exelixis Inc (EXEL)

Total Score

19 out of 29

Currently on the following lists
Growth Stock List
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for EXEL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for EXEL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for EXEL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for EXEL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Financial Details for EXEL

Company Overview

Company Name Exelixis Inc
Country USA
Description Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Sector Name TRADE & SERVICES
Industry Name SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Most Recent Quarter 10/31/2022
Next Earnings Date 2/15/2023

Stock Price History

Last Day Price 17.04
Last Day Volume 1,824,151
Average Daily Volume 1,945,432
52-Week High 23.40
52-Week Low 14.87
Last Price to 52 Week Low 14.59 %

Valuation Measures

Trailing PE 18.17
Industry PE 34.63
Sector PE 74.05
5-Year Average PE 28.10
Free Cash Flow Ratio 3.55
Industry Free Cash Flow Ratio 36.49
Sector Free Cash Flow Ratio 57.06
Book Value Per Share Most Recent Quarter 7.72
Price to Book Ratio 2.19
Industry Price to Book Ratio 4.81
Sector Price to Book Ratio 7.86
Price to Sales Ratio Twelve Trailing Months 3.36
Industry Price to Sales Ratio Twelve Trailing Months 5.73
Sector Price to Sales Ratio Twelve Trailing Months 1.91

Share Statistics

Total Shares Outstanding 322,561,000
Market Capitalization 5,496,439,440
Institutional Ownership 0.00 %

Dividends

Ex-Dividend Date
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00 %
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Average Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio 0.00 %

Income Statement

Quarterly Earnings Growth YOY 89.40 %
Annual Earnings Growth 106.71 %
Reported EPS Past Year 0.66
Reported EPS Prior Year 0.71
Net Income Twelve Trailing Months 307,621,000
Net Income Past Year 231,063,000
Net Income Prior Year 111,781,000
Quarterly Revenue Growth YOY 25.40 %
5-Year Revenue Growth 33.45 %

Balance Sheet

Total Cash Per Share 4.80
Total Cash Most Recent Quarter 1,546,992,000
Total Cash Past Year 1,467,074,000
Total Cash Prior Year 1,206,536,000
Net Cash Position Most Recent Quarter 1,546,992,000
Net Cash Position Past Year 1,467,074,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Current Ratio Most Recent Quarter 6.10
Total Stockholder Equity Past Year 2,210,615,000
Total Stockholder Equity Prior Year 1,879,113,000
Total Stockholder Equity Most Recent Quarter 2,491,402,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

MACD 0.09
MACD Signal 0.09
20-Day Bollinger Lower Band 18.13
20-Day Bollinger Middle Band 19.56
20-Day Bollinger Upper Band 21.00
Beta 0.70
RSI 56.11
50-Day SMA 19.17
200-Day SMA 20.43

System

Modified 12/1/2022 9:06:26 AM